Altimmune (ALT) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALT shares.
View ALT analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1 year price targets for Altimmune's stock. Their ALT share price forecasts range from $6.00 to $50.00. On average, they predict the company's stock price to reach $26.14 in the next twelve months. This suggests a possible upside of 547.1% from the stock's current price.
View analysts price targets for ALT or view top-rated stocks among Wall Street analysts.

Altimmune's stock was trading at $16.45 on January 1st, 2023. Since then, ALT stock has decreased by 75.4% and is now trading at $4.04.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ALT earnings forecast.

Altimmune, Inc. (NASDAQ:ALT) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. The firm had revenue of $0.02 million for the quarter. Altimmune had a negative trailing twelve-month return on equity of 45.37% and a negative net margin of 2,618.74%.

ETFs with the largest weight of Altimmune (NASDAQ:ALT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ETFMG Treatments Testing and Advancements ETF (GERM), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), Invesco DWA SmallCap Momentum ETF (DWAS) and

Shares of Altimmune reverse split on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Vaxart (VXRT), Pfizer (PFE), Verizon Communications (VZ), Amarin (AMRN), Advanced Micro Devices (AMD), Albireo Pharma (ALBO), Alliance Data Systems (ADS), AcelRx Pharmaceuticals (ACRX), Albertsons Companies (ACI) and Achieve Life Sciences (ACHV).

Altimmune trades on the NASDAQ under the ticker symbol "ALT."

Altimmune's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (10.06%), Ardsley Advisory Partners LP (2.94%), BlackRock Inc. (2.83%), Two Sigma Investments LP (2.12%), Two Sigma Advisers LP (1.93%) and Dimensional Fund Advisors LP (1.15%). Insiders that own company stock include David Drutz, Diane Jorkasky, Klaus Schafer, M Scot Roberts, Matthew Scott Harris, Philip Hodges, Venrock Healthcare Capital Par, Vipin K Garg and Wayne Pisano.
View institutional ownership trends.

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALT stock can currently be purchased for approximately $4.04.

Altimmune (NASDAQ:ALT) has a market capitalization of $199.13 million and generates $4.41 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis.

Altimmune's mailing address is 910 CLOPPER ROAD SUITE 201S, GAITHERSBURG MD, 20878. The official website for the company is altimmune.com. The company can be reached via phone at (240) 654-1450, via email at arr@lifesciadvisors.com, or via fax at 410-269-2601.